Answers are grounded in this paper and cite their sources.
This review highlights the role of neurohormonal derangements in chronic heart failure and explores potential therapeutic strategies targeting anabolic axes.
Chronic heart failure (CHF) involves derangements in multiple neurohormonal axes leading to a procatabolic state and wasting syndrome associated with significant mortality. Catabolic abnormalities include excess catecholamines and glucocorticoids. Anabolic defects include deficiencies of sex steroids, insulin resistance, and growth hormone (GH) resistance. These abnormalities are also correlated with increased morbidity and mortality in CHF. Anabolic axes have been augmented in pilot studies in CHF with testosterone, GH, insulin-like growth factor-1, and GH secretagogues. Results have been varied although some treatments have been associated with improved surrogate endpoints. This review article explores the current understanding of metabolic derangements in CHF and highlights potential neuroendocrine treatment strategies.
No takes yet. Share an insight, caveat, or question.
Chaggar et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: